Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Bladder Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Bladder Cancer
    New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
    TopAbstracts in Bladder Cancer 07/02/2008 - (DGNews)
    Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
    TopAbstracts in Bladder Cancer 06/04/2008 - (DGNews)
    TopAbstracts in Bladder Cancer 05/07/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Bladder Cancer

    Webcasts/CME archive

     Recent cases - Bladder Cancer
      Adenocarcinoma of the Bladder Following Nephrogenic Adenoma: A Case Report
      The First Case of Vesico-Vaginal Fistula in a Patient with Primary Lymphoma of the Bladder: A Case Report
      Vacuum-Assisted Closure Therapy in Ureteroileal Anastomotic Leakage after Surgical Therapy of Bladder Cancer
      Granular Cell Tumors of the Urinary Bladder
      Granulomatous Hepatitis after Intravesical BCG Treatment for Bladder Cancer

      Cases archive
        




      my personal edition > bladder cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Office Fulguration Confirmed as Valuable Procedure for Selected Recurrent Papillary Tumors: Presented at AUA

      By Jill Stein

      CHICAGO, IL -- April 29, 2003 -- Cystodiathermy conducted in the physician's office is safe and effective for treatment of selected patients with recurrent small low-grade papillary bladder tumors, according to data presented here April 28th at the 2003 Annual Meeting of the American Urological Association.

      The study was conducted by a group from Memorial Sloan-Kettering Cancer Center in New York. Dr. Amanda North, who is now with Montefiore Hospital in New York, reported the findings.

      Her group prospectively followed 267 consecutive patients with superficial bladder cancer undergoing routine office surveillance cystoscopy during a recent 2-year period.

      All patients completed their initial treatment and at least 6 months of surveillance without tumor recurrence.

      "Flexible cystoscopy is an established method of performing office surveillance in patients with superficial bladder cancer," Dr. North explained. "Low-grade superficial papillary tumors can be identified by endoscopy, and such tumors rarely progress in stage. Although recurrent papillary tumors are usually treated with transurethral resection under anesthesia, small papillary tumors may be treated in the office using cystodiathermy."

      At Memorial Sloan-Kettering, physicians have been performing office fulguration for 15 years. However, the safety and efficacy of the technique had never been shown in a clinical trial.

      In the study, selection criteria for fulguration included the presence of fewer than 5 low grade-appearing papillary tumors, less than 0.5 cm tumor size, negative urine cytology, and the patient's wish to undergo an office-based treatment.

      Of study subjects, 75.4% were men. The median age was 61.1 years, 65.5% had a history of intravesical therapy, 13.9% had a history of upper tract tumor, and 75.5% had a history of recurrent cancer. Seventy-five percent were current or former smokers.

      One hundred twenty-three patients (46%) developed at least 1 tumor recurrence at a median 2.6 years of follow-up, Dr. North said. Seventy-four (60%) of the 123 patients who had a recurrence underwent office fulguration. The other 53 (40%) patients had conventional transurethral resection under general anesthesia.

      Results showed no difference in disease-specific survival or disease progression in the group that underwent the office procedure compared with the control group that underwent the standard transurethral resection.

      Among high-risk patients with low-grade papillary recurrences, those who underwent office cystodiathermy did not risk disease progression and had a better overall survival.

      Flexible cystodiathermy in the office is a safe and effective method for treating small low-grade recurrent superficial papillary tumors in appropriately selected patients, Dr. North said. "If there is any question that the tumor might be invasive or that there might be some carcinoma in situ, patients should be taken to the operating room," she added.

      The next step in the research is to compare the cost-effectiveness of the procedure with that of the standard transurethral resection, she said.


      [Study title: Efficacy of Office Fulguration for Recurrent Low Grade Papillary Bladder Tumors Under 0.5 centimeters (CM). Abstract 1002]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send